{"ticker": {"uuid": "841b9dd7-c5c2-4501-a0e5-ca537d28f0bb", "symbol": "ABUS", "name": "Arbutus Biopharma Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Arbutus, Sanofi escalate mRNA patent fights; InnoCare\u2019s TYK2 contender advances", "summary": "", "url": "https://finance.yahoo.com/m/d51219c9-6fcf-3e94-95b2-4484b88bc370/arbutus%2C-sanofi-escalate-mrna.html", "source_name": "BioPharma Dive", "published_at": "2026-07-17T10:07:25+00:00", "published_display": "17 Jul 2026 10:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arbutus (ABUS) Plans Share Buyback Program Starting Q3", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQNDR4bFg1dGdNYnBKYUZaamxPcHF6eTZHckZaMDZiSHU1bm9qVG51MmYzekdYeWowOGNWVE1UMXhyVWJfRVVxNHREdWtaUDh0NUdFdkpyVWZqdXBnUHlXcndMdVZSNE44cDNfd21ERERhcTZPbFVCLW1FRzlsU0hJOVd4WGRLTXU1OGROYzZpbTBEa19XZm5vallxRzR4aDlHSzV3UW5R?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T13:52:30+00:00", "published_display": "16 Jul 2026 13:52", "sentiment": "positive", "sentiment_pct": 62, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNT Over Patent Dispute", "summary": "Arbutus Biopharma (ABUS) and Genevant Sciences have filed three international lawsuits against Pfizer and BioNTech, alleging patent infringement related to their COVID-19 vaccine's lipid nanoparticle technology. This action follows a similar U.S. dispute and a $178 million settle", "url": "https://www.gurufocus.com/news/8962496/arbutus-biopharma-abus-files-lawsuits-against-pfizer-and-biontech-over-patent-dispute?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-16T14:42:22", "published_display": "16 Jul 2026 14:42", "sentiment": "negative", "sentiment_pct": 39, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNTech Over Patent Dispute", "summary": "Arbutus Biopharma (ABUS) and Genevant Sciences have initiated three international lawsuits against Pfizer and BioNTech, alleging patent infringements related to their COVID-19 vaccine's lipid nanoparticle technology. This action follows a prior U.S. dispute and a $178 million set", "url": "https://www.gurufocus.com/news/8962496/arbutus-biopharma-abus-files-lawsuits-against-pfizer-and-biontech-over-patent-dispute", "source_name": "GuruFocus", "published_at": "2026-07-16T13:18:38", "published_display": "16 Jul 2026 13:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arbutus-biopharma-genevant-sue-pfizer-121613854.html", "source_name": "MT Newswires", "published_at": "2026-07-16T12:16:13+00:00", "published_display": "16 Jul 2026 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus (ABUS) Secures $178 Million Settlement with Moderna", "summary": "Arbutus Biopharma Corp (ABUS) has secured a $178 million settlement with Moderna to resolve patent infringement disputes related to Moderna\u2019s COVID-19 vaccines. This payment will bolster Arbutus's cash reserves and allow it to focus on its core business of developing therapeutics", "url": "https://www.gurufocus.com/news/8962282/arbutus-abus-secures-178-million-settlement-with-moderna", "source_name": "GuruFocus", "published_at": "2026-07-16T12:52:38", "published_display": "16 Jul 2026 12:52", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return", "summary": "Arbutus Biopharma and its licensee Genevant have filed three international lawsuits against Pfizer and BioNTech for patent infringement related to their lipid nanoparticle technology, seeking monetary damages and injunctions. This follows Arbutus receiving approximately $178 mill", "url": "https://www.quiverquant.com/news/Arbutus+Biopharma+Files+International+Patent+Lawsuits+Against+Pfizer+and+BioNTech,+Announces+Moderna+Settlement+Payment+and+Plans+for+Capital+Return", "source_name": "Quiver Quantitative", "published_at": "2026-07-16T11:42:00", "published_display": "16 Jul 2026 11:42", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (Nasdaq: ABUS) receives $178M from Moderna, eyes $230M buyback", "summary": "Arbutus Biopharma received approximately $178 million from a settlement with Moderna regarding mRNA patent disputes and may receive up to an additional $1.3 billion. The company also announced plans to return up to $230 million to shareholders through common share repurchases, co", "url": "https://www.stocktitan.net/sec-filings/ABUS/8-k-arbutus-biopharma-corp-reports-material-event-8aef31b3971d.html", "source_name": "Stock Titan", "published_at": "2026-07-16T11:41:38", "published_display": "16 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders", "summary": "Arbutus Biopharma, and its licensee Genevant, have initiated three international lawsuits against Pfizer and BioNTech for patent infringement related to their innovative LNP technology used in COVID-19 vaccines. Concurrently, Arbutus announced the receipt of approximately $178 mi", "url": "https://www.stocktitan.net/news/ABUS/arbutus-initiates-international-patent-infringement-enforcement-vns5sthqsuwn.html", "source_name": "Stock Titan", "published_at": "2026-07-16T11:41:38", "published_display": "16 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma: Moderna Validates My IP Bull Case (NASDAQ:ABUS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNdHBKNC05NEd2M0k1eUJ3UzRfc002YTh3S2JldER5U3RoSmFObnNpRU5yQllSTmtiSlJYT3A2cVhHQ0FlaThUZkRUbEhaZU1EYS1BVEpvaVI0Yy1zeTkwUDBLOWtjcHlOQnY1TXNhRTlURzB3aXJYQUVEclNsR1hvd25CVDJhcU1lX3J2TTN4UWwzRmtJOVFj?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-13T12:00:00+00:00", "published_display": "13 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arbutus Biopharma stock hits 52-week high at 5.34 USD By Investing.com", "summary": "Arbutus Biopharma's stock reached a 52-week high of $5.34, reflecting strong investor confidence with a 56% return over the past year and a market capitalization of $1.05 billion. The company holds an \"EXCELLENT\" financial health score and its drug imdusiran recently received Fas", "url": "https://ng.investing.com/news/stock-market-news/arbutus-biopharma-stock-hits-52week-high-at-534-usd-93CH-2593526", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T17:15:49", "published_display": "09 Jul 2026 17:15", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks", "summary": "Arbutus Biopharma (ABUS) has been added to the Russell 2000 Growth Defensive and Russell 2000 Defensive Indexes, while simultaneously being removed from several value-oriented Russell indexes. This reclassification may influence the types of index-linked funds and mandates that h", "url": "https://finance.yahoo.com/markets/stocks/articles/arbutus-biopharma-abus-joins-russell-221151130.html", "source_name": "Market source", "published_at": "2026-07-09T15:11:00", "published_display": "09 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma stock hits 52-week high at 5.34 USD", "summary": "Arbutus Biopharma's stock has reached a new 52-week high of $5.34, reflecting strong investor confidence and a 56% return over the past year. The company, with a market capitalization of $1.05 billion, has an \"EXCELLENT\" financial health score and an impressive gross profit margi", "url": "https://www.investing.com/news/company-news/arbutus-biopharma-stock-hits-52week-high-at-534-usd-93CH-4784445", "source_name": "Investing.com", "published_at": "2026-07-09T10:30:00", "published_display": "09 Jul 2026 10:30", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) Stock Looks Reasonable On Earnings But Stretched On Value", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxOQ1U0b3BNbGJVUFFkMFVGbWlBMXo2SVRpR2dqN09WdzdCYWo3Vm14VDRjU252OWttSWxrYnlWZWo1bkwwZzFwM0ZEU0owb0tTTTZ5bmhoQXhiTnFtNzFRb1VJYzB0eU11RmgxMUVQWERjX0JTaTJlMk9Ka2JwNm4wd3RNSFA2dXVWYW1FcGdhd1ZxeFVjckMyNk1TME9iR1ROZ3NKZ0pYckVrVUdJWEFYbGQySlU1ZnlLQTB2YnJLcUVUajM3RGRLd2JjZ2s3U2pLWUtZSWlDOUFoUndVbVFqc1J0ZlJPZ9IB6wFBVV95cUxQWVdyblFvVDhvWE03a1VTMlZZX3MyOUxIYTREcFVxOS1oV3V6R1Y1YjBSU3p4aTVtaldOU1AyLTdTUjNwak5TUWk1bFlXeXVhSzZ1X3AyWGQtQ0NBSXp4RldQaHgwVXdsS1l4SV8wYUNLNmJycUtsWjB3V0RIYVd0cmZzd1JBRkNMcUFDNlQ4NmpBdHU1c2dfV0JkTVBWcnhTbWt4OWx0dFBxSUc4YVZpY0pNRTdacVZIUVRkSWVKeFYyLW5VQmNXWVhwY25DMUtUYmJ6WlhnaXFVSHlURjZraWhFaXVQVjk2WGxJ?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABUS - Arbutus Biopharma Corp Options", "summary": "This article provides a detailed overview of Arbutus Biopharma Corp (ABUS) stock options and key financial metrics. It includes recent stock performance, company financials like market cap, income, sales, and various ratios, along with insider and institutional ownership data. Th", "url": "https://finviz.com/stock?t=ABUS&ta=1&p=d&ty=oc&ov=chain_date&e=2026-09-18", "source_name": "Finviz", "published_at": "2026-06-27T09:41:26", "published_display": "27 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp (ABUS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Arbutus Biopharma Corp (ABUS), noting its current valuation score of 8.58, which ranks it 115 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of 5.38, which is slightly below ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abus/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T18:09:38", "published_display": "23 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "The article provides a technical analysis of Arbutus Biopharma Corp (ABUS), focusing on its support and resistance levels, various technical indicators, and moving averages. It highlights that ABUS currently has a price momentum score of 8.98 and is trading between a resistance l", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abus/technical", "source_name": "TradingKey", "published_at": "2026-06-18T04:09:20", "published_display": "18 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Arbutus Biopharma Corp (ABUS) has an earnings forecast score of 8.67, ranking well within the Biotechnology & Medical Research industry. Analysts provide an average price target of $5.00 with a Buy rating. The company's expected revenue for the next quarter is $450.00K, and the E", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abus/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T23:09:10", "published_display": "17 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp (ABUS) Institutional Confidence", "summary": "The article details the institutional confidence score for Arbutus Biopharma Corp (ABUS), which currently stands at 5.00, ranking it 133rd out of 388 in its industry. Institutional shareholding has increased to 65.56%, a 3.63% quarter-over-quarter rise. The largest institutional ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abus/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T02:40:15", "published_display": "17 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp (ABUS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Arbutus Biopharma Corp (ABUS), identifying its major shareholders, their proportional holdings, and the types of shareholders. It also provides institutional shareholding data over various quarters and lists related ETFs that hold", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abus/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T02:39:43", "published_display": "17 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results", "summary": "Arbutus Biopharma Corporation (ABUS) announced significant Q1 2026 results, reporting $179.1 million in revenue, a substantial increase from $1.8 million a year prior, largely due to a litigation settlement with Moderna. The company swung from a $24.5 million loss to a net income", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arbutus-biopharma-corporation-abus-reports-180646496.html", "source_name": "Market source", "published_at": "2026-06-13T18:06:00", "published_display": "13 Jun 2026 18:06", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (Nasdaq:ABUS) - Stock Analysis", "summary": "Arbutus Biopharma (ABUS) is a clinical-stage biopharmaceutical company focused on developing therapies for infectious diseases, particularly chronic Hepatitis B virus (HBV). The company became profitable this year, exceeding analyst expectations for its first quarter 2026 earning", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abus/arbutus-biopharma", "source_name": "Simply Wall Street", "published_at": "2026-06-12T01:09:11", "published_display": "12 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) director awarded fully vested options on 78,800 shares", "summary": "Arbutus Biopharma director Roger Sawhney was granted fully vested stock options for 78,800 common shares at an exercise price of $4.24 per share, matching the closing price on the grant date of June 8, 2026. This equity compensation award is immediately exercisable and expires on", "url": "https://www.stocktitan.net/sec-filings/ABUS/form-4-arbutus-biopharma-corp-insider-trading-activity-ca4f1b555104.html", "source_name": "Stock Titan", "published_at": "2026-06-11T01:38:55", "published_display": "11 Jun 2026 01:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Arbutus Biopharma Corp Insider Trading Activity", "summary": "Arbutus Biopharma director Robert A. Beardsley was granted 78,800 fully vested stock options with an exercise price of $4.24 per share, expiring on June 8, 2036. This transaction is categorized as a compensation-related award, not an open-market purchase or sale. The options are ", "url": "https://www.stocktitan.net/sec-filings/ABUS/form-4-arbutus-biopharma-corp-insider-trading-activity-30701fb514c4.html", "source_name": "Stock Titan", "published_at": "2026-06-10T19:40:13", "published_display": "10 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABUS - Arbutus Biopharma Corp Stock Price and Quote", "summary": "This page provides a comprehensive overview of Arbutus Biopharma Corp (ABUS) stock, including its latest trading data, financial metrics, analyst ratings, and recent news headlines. Key financial figures like market cap, income, sales, and employee count are listed, alongside per", "url": "https://finviz.com/stock?t=ABUS", "source_name": "Finviz", "published_at": "2026-05-29T20:09:39", "published_display": "29 May 2026 20:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders at Arbutus Biopharma (NASDAQ: ABUS) approve 2026 share plan and auditor", "summary": "Arbutus Biopharma Corporation's shareholders approved the 2026 Omnibus Share and Incentive Plan, authorizing 16,300,000 common shares for equity-based compensation. They also re-elected all director nominees, approved executive compensation on a non-binding advisory basis, and ra", "url": "https://www.stocktitan.net/sec-filings/ABUS/8-k-arbutus-biopharma-corp-reports-material-event-97792fed8f39.html", "source_name": "Stock Titan", "published_at": "2026-05-27T19:39:25", "published_display": "27 May 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake", "summary": "Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi have reported a beneficial ownership of 18,557,543 common shares, representing a 9.4% stake in Arbutus Biopharma Corporation (NASDAQ: ABUS). This stake is held through two funds: Two Seas Global (Master) Fund LP and Tw", "url": "https://www.stocktitan.net/sec-filings/ABUS/schedule-13g-a-arbutus-biopharma-corp-amended-passive-investment-disc-cfc15ead65a6.html", "source_name": "Stock Titan", "published_at": "2026-05-16T00:35:59", "published_display": "16 May 2026 00:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "Arbutus Biopharma Corporation reported strong first-quarter 2026 financial results, including $179.1 million in total revenue, primarily from a litigation settlement with Moderna. The company also announced that its investigational drug, imdusiran, received Fast Track designation", "url": "https://finance.yahoo.com/news/arbutus-reports-first-quarter-2026-113000313.html", "source_name": "Market source", "published_at": "2026-05-14T00:40:17", "published_display": "14 May 2026 00:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp reports results for the quarter ended March 31 - Earnings Summary", "summary": "Arbutus Biopharma Corp (ABUS) has reported its financial results for the quarter ended March 31. This earnings summary provides a brief overview of the company's performance during the specified period.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41Q1M1:0-arbutus-biopharma-corp-reports-results-for-the-quarter-ended-march-31-earnings-summary/", "source_name": "TradingView", "published_at": "2026-05-14T00:09:11", "published_display": "14 May 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Swings to Profit in Q1, Revenue Rises; Shares Up Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/news/arbutus-biopharma-swings-profit-q1-114714905.html", "source_name": "MT Newswires", "published_at": "2026-05-13T11:47:14+00:00", "published_display": "13 May 2026 11:47", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma earnings beat by $0.91, revenue topped estimates", "summary": "Arbutus Biopharma (NASDAQ: ABUS) exceeded analyst expectations for its first-quarter earnings, reporting an EPS of $0.870 against an estimated $-0.040. The company's revenue also significantly topped estimates, coming in at $179.23M compared to the consensus of $400K. The stock h", "url": "https://www.investing.com/news/earnings/arbutus-biopharma-earnings-beat-by-091-revenue-topped-estimates-4684337", "source_name": "Investing.com", "published_at": "2026-05-13T12:39:54", "published_display": "13 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) Reports Strong Q1 Earnings with $0.87 EPS", "summary": "Arbutus Biopharma (ABUS) reported strong Q1 earnings with a GAAP EPS of $0.87 and revenue of $179.1 million, significantly boosted by a litigation settlement with Moderna. The FDA also granted fast track status to its lead asset, enhancing growth prospects. Despite a strong finan", "url": "https://www.gurufocus.com/news/8855072/arbutus-biopharma-abus-reports-strong-q1-earnings-with-087-eps", "source_name": "GuruFocus", "published_at": "2026-05-13T12:39:54", "published_display": "13 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/arbutus-q1-earnings-snapshot-113607386.html", "source_name": "Associated Press", "published_at": "2026-05-13T11:36:07+00:00", "published_display": "13 May 2026 11:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp 1Q 2026: Revenue $179.13M, EPS $0.87\u2014 10-Q Summary", "summary": "Arbutus Biopharma Corp reported a significant increase in first-quarter 2026 revenue to $179.13 million and diluted EPS of $0.87, driven primarily by a $178.7 million licensing settlement with Moderna. The company also highlighted pipeline progress for imdusiran, which received F", "url": "https://www.tradingview.com/news/tradingview:eefe9e5400205:0-arbutus-biopharma-corp-1q-2026-revenue-179-13m-eps-0-87-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-13T11:39:54", "published_display": "13 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna settlement drives Arbutus (NASDAQ: ABUS) to $169.7M Q1 profit", "summary": "Arbutus Biopharma reported a significant Q1 2026 profit of $169.7 million, primarily driven by a $178.7 million license revenue from its share of Genevant's settlement with Moderna. This settlement, which includes a noncontingent payment and a potential contingent payment of up t", "url": "https://www.stocktitan.net/sec-filings/ABUS/10-q-arbutus-biopharma-corp-quarterly-earnings-report-e2a90b2069e8.html", "source_name": "Stock Titan", "published_at": "2026-05-13T11:39:54", "published_display": "13 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus (NASDAQ: ABUS) swings to Q1 profit on $179M revenue surge", "summary": "Arbutus Biopharma (NASDAQ: ABUS) reported a significant turnaround in Q1 2026, swinging to a net income of $169.7 million on $179.1 million in revenue, primarily driven by a litigation settlement with Moderna. The company expects to receive $178.7 million from a $950 million upfr", "url": "https://www.stocktitan.net/sec-filings/ABUS/8-k-arbutus-biopharma-corp-reports-material-event-9c010d7c3df7.html", "source_name": "Stock Titan", "published_at": "2026-05-13T11:39:53", "published_display": "13 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early (NASDAQ:ABUS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNRlZjVnZsODlzQTVtQTREOC1mdjNvSkdWTW5QNnNWeHdSZ1l2OUk2aS1Oa3VNNzE3YjM4alhra1kteGlVaThIWGNNLUtmLVI0YWZ0Z2RpNGtacFNnUTAxRjc1UG1qVVpDMXRSNnc3R1h4WnRDQzI4SnpDQnc0N2pyVEZLWGtQRG1oUWhCUjExR3RyTnFkY203eVBrRERIM3VHbzlNZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxObl9XWW5Ic2JBNUpoSWltc1pHb0o5aWJRZk1NRzZ2VGpyUTRCMjduVTN4N3ZjdVYwY2RGS3dBOWo3TlFTNWQtRnF6YkRNMG44eVdRMU5TOFA5YmtTNHFHSWpYMXZ0ZTZOaW1TRGRtUHJoRXlrbThnSTF4UEhnZ3h5MlNyZ2R6UzJkOXlZUm9fSGFyaDk4ODlqaDlxRnNrWHdj?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQSXJKN05RQ2l5V2dudzlLYWt0dUIwSG84R1k2SHEtaUhxVElQeldnWDRINE1FMFlEa0FMczFFbzh5TjN5cEc3WEZ1dWhTMzFoMnZqeUlGZ1FHSnBCWlFueUZuNDI0aDhIbjhCSWIwc05aTnJNV3d2RU9CTnJoTVplek9HTl9PcUU5RmxuX0kwek5Ba2JkM09SS0pQT2RYeFZnSEE?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNdTRuMEY3c0p2dWVlMkRPc1FVcHFwelZ1czA3b2VVTVF5SGJJOGRoMVBoRTFDOWJfbU1hXzBSU1RKRVFhdmREaDRleXFrbXh5bmoyMmZTV25BM0JPQ3A4N2xpMjhra211Y1lWbXpHM1dDVWdqUEpiTl91d2hfaVluWGVVc1UxWEdpVGlEdS1EZHdIOHg0M3ZKa0V5dGlyYjhGLUpXV0FGSmJSdw?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp ($ABUS) Former Interim President and CEO 2025 Pay Revealed | ABUS Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNTUNWYzRqSm5LR1VadjdUV0Z0RTA1cE81WHBWbXNNSUxtdjVNVGFaYUZfWDZ2cGlEMmt3QWZCX0Jlc0tHOUJzZGdMck9uNmhRSE1EaTR5YTZFZk5fNW96X3A4Njltb0FxWFc1TzM2OUhnZ3YwS1JjR1kwYllUaFBDVkl0a3NzclVyMVVCbFZJeFJjSEtCQV9GYm13QUJ0bThIc3Z0VXJnZW9rd080SzRvbVplb0xXMlQtUEpvbw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNbnk4YVVtS0dKamplaGRucDhPcm9wLUpOMTYwMWdXNFAyZlBKS09rM3JIcmFLMURiTWgwYWFDeDlnLUJQZ1JFQjd3czF5ZE80TG9FMzhZUWQ0Z055Z1JseENuSEFyYmhQNmw5MnhqeTFyQm1KWFczdTM1TDZWc0dUWWt2NTFJbUlOa3laSTlidGw0OXpReS1TT1U2UlQ2ZEZRX01tZlJB?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwJBVV95cUxOckYwNGExSUtWSE1aZmFCRDdyX0dZZUk2a242WndQZFBpWk8wcnF0bjY5Vnp2ZzNzLWNVRFlGdjBKTFctY2hVeWZhOHpFRHNSb3hJYmp2T1FISHlwVld5RUIwaEVUSnNlNE9salg3SFBnc0VEUzUtNm1XZFhnVU1KSnRtcUpMaTlxUmxabWptTVAtOWFTZVZvaHhLUXJ0eFhlUDYxaWREUXBiQllReTJhZ1dtZGdDXzI1UTR0QnlXbFNxckljUmkxZkpmWEtfMXZUUWZpUjBOUzNqTjNIcUdBampDWVBWWFNDTUFqN0I2NGx2VURiSk9McXFiWTdVWnN5bGRRODJMTXVGNGZVT1E4?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxPX005QmFWeDhvalp1c0Nla1k0MC1oZlNHLUlEdFp5REZYaFVFaUp3Vmo5ak44a29PSjZsaHRFTV9ObFFPY0l3NFpHMFJ6T1A3eHY1Q1U4d0s2QXVGU0NTOS0tZEhKcUw2Z2tUbXZiWkhBRHhvVGhTRlF4dmt5clh4ajJNRC1DNHU2MV8tdGtIU2ZVTzlCV2pEWFhCQkxLSVhhMUhNRjhtOVFpbG9jSW9GcWQxb09KSVZCdW5uSF84RmtsaEhibmltN1RfcjlrRDk0bVJPeW9Da3ZvUHhhREVSVlJOdk9qTU8xeUp2SWhZaG8xX0lHYWhsbWo0RFE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European Patent Office revokes Arbutus Biopharma patent following appeal", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNN0cxRWkyNkU4RFJteU95eVdYeS1haG4wdE9wRkZ5STcweEg0emVNbW9KUnNuZzREV0w1MkFCRGZHd1ZEQlZ3bUhoZHJiOHZxMmZOYm1MZWZVdEpBR3R5dHdxRldEejhDNHRfQVBfNzhFUXEtbTY2NllsVXFDU0hGM3JpNExiOERNUko3VE0yUmRMUVNCQmpna0JqeHVBVkxVclppOGR6bWRQQzRpUDdxT3RuVVRaUk1nTWZueHNUUTdnUFo2TjA4?oc=5", "source_name": "Investing.com", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus falls as patent dispute with Moderna hits EU snag", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPTkM2RTNaMFlfUHlTNGU2VzNSVnVfTlFfS1ZnQjJ1bGF5aXhsOGNYVlROLU1RVXZ1bElRTmVHNUlhSGVmTEIwY0FiZlVpRnd2c3Vtdmc5dERCUmVaX0VWMW9YeWQ5OE1WN0ZfSUQ3SWtueUpkWlhxSHlfTW9kNUU0LUxybk1Dc1pyb1Zn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corporation (ABUS) Stock Price Today: $4.74", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE93NnRvQV91Ri05VWkzdXpsdTlNTmZwUTFFem8tVkFnRmd6MjdtWmtDZmZjMUlYRnpZSmFmeGM2QnM4OWVDWmVvOVBFelNLTFFITVNPQU1Nbw?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T00:30:45+00:00", "published_display": "13 Jan 2026 00:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharm (ABUS) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5pTjAzRUd4S2N3eXk0SUR4ajFCVXhMLUxscUp5ajZiSEJKRG5RMmFWUjdjREczekU3SGxMRVBESmZKcnJnNGxZRWNEam03UzBpcHFn?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:02:24+00:00", "published_display": "25 Apr 2025 00:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Arbutus, Sanofi escalate mRNA patent fights; InnoCare\u2019s TYK2 contender advances", "summary": "", "url": "https://finance.yahoo.com/m/d51219c9-6fcf-3e94-95b2-4484b88bc370/arbutus%2C-sanofi-escalate-mrna.html", "source_name": "BioPharma Dive", "published_at": "2026-07-17T10:07:25+00:00", "published_display": "17 Jul 2026 10:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus (ABUS) Plans Share Buyback Program Starting Q3", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQNDR4bFg1dGdNYnBKYUZaamxPcHF6eTZHckZaMDZiSHU1bm9qVG51MmYzekdYeWowOGNWVE1UMXhyVWJfRVVxNHREdWtaUDh0NUdFdkpyVWZqdXBnUHlXcndMdVZSNE44cDNfd21ERERhcTZPbFVCLW1FRzlsU0hJOVd4WGRLTXU1OGROYzZpbTBEa19XZm5vallxRzR4aDlHSzV3UW5R?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-16T13:52:30+00:00", "published_display": "16 Jul 2026 13:52", "sentiment": "positive", "sentiment_pct": 62, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNT Over Patent Dispute", "summary": "Arbutus Biopharma (ABUS) and Genevant Sciences have filed three international lawsuits against Pfizer and BioNTech, alleging patent infringement related to their COVID-19 vaccine's lipid nanoparticle technology. This action follows a similar U.S. dispute and a $178 million settle", "url": "https://www.gurufocus.com/news/8962496/arbutus-biopharma-abus-files-lawsuits-against-pfizer-and-biontech-over-patent-dispute?mobile=true", "source_name": "GuruFocus", "published_at": "2026-07-16T14:42:22", "published_display": "16 Jul 2026 14:42", "sentiment": "negative", "sentiment_pct": 39, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNTech Over Patent Dispute", "summary": "Arbutus Biopharma (ABUS) and Genevant Sciences have initiated three international lawsuits against Pfizer and BioNTech, alleging patent infringements related to their COVID-19 vaccine's lipid nanoparticle technology. This action follows a prior U.S. dispute and a $178 million set", "url": "https://www.gurufocus.com/news/8962496/arbutus-biopharma-abus-files-lawsuits-against-pfizer-and-biontech-over-patent-dispute", "source_name": "GuruFocus", "published_at": "2026-07-16T13:18:38", "published_display": "16 Jul 2026 13:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma, Genevant sue Pfizer, BioNTech Over Lipid Nanoparticle Patents", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/arbutus-biopharma-genevant-sue-pfizer-121613854.html", "source_name": "MT Newswires", "published_at": "2026-07-16T12:16:13+00:00", "published_display": "16 Jul 2026 12:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus (ABUS) Secures $178 Million Settlement with Moderna", "summary": "Arbutus Biopharma Corp (ABUS) has secured a $178 million settlement with Moderna to resolve patent infringement disputes related to Moderna\u2019s COVID-19 vaccines. This payment will bolster Arbutus's cash reserves and allow it to focus on its core business of developing therapeutics", "url": "https://www.gurufocus.com/news/8962282/arbutus-abus-secures-178-million-settlement-with-moderna", "source_name": "GuruFocus", "published_at": "2026-07-16T12:52:38", "published_display": "16 Jul 2026 12:52", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return", "summary": "Arbutus Biopharma and its licensee Genevant have filed three international lawsuits against Pfizer and BioNTech for patent infringement related to their lipid nanoparticle technology, seeking monetary damages and injunctions. This follows Arbutus receiving approximately $178 mill", "url": "https://www.quiverquant.com/news/Arbutus+Biopharma+Files+International+Patent+Lawsuits+Against+Pfizer+and+BioNTech,+Announces+Moderna+Settlement+Payment+and+Plans+for+Capital+Return", "source_name": "Quiver Quantitative", "published_at": "2026-07-16T11:42:00", "published_display": "16 Jul 2026 11:42", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (Nasdaq: ABUS) receives $178M from Moderna, eyes $230M buyback", "summary": "Arbutus Biopharma received approximately $178 million from a settlement with Moderna regarding mRNA patent disputes and may receive up to an additional $1.3 billion. The company also announced plans to return up to $230 million to shareholders through common share repurchases, co", "url": "https://www.stocktitan.net/sec-filings/ABUS/8-k-arbutus-biopharma-corp-reports-material-event-8aef31b3971d.html", "source_name": "Stock Titan", "published_at": "2026-07-16T11:41:38", "published_display": "16 Jul 2026 11:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders", "summary": "Arbutus Biopharma, and its licensee Genevant, have initiated three international lawsuits against Pfizer and BioNTech for patent infringement related to their innovative LNP technology used in COVID-19 vaccines. Concurrently, Arbutus announced the receipt of approximately $178 mi", "url": "https://www.stocktitan.net/news/ABUS/arbutus-initiates-international-patent-infringement-enforcement-vns5sthqsuwn.html", "source_name": "Stock Titan", "published_at": "2026-07-16T11:41:38", "published_display": "16 Jul 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma: Moderna Validates My IP Bull Case (NASDAQ:ABUS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNdHBKNC05NEd2M0k1eUJ3UzRfc002YTh3S2JldER5U3RoSmFObnNpRU5yQllSTmtiSlJYT3A2cVhHQ0FlaThUZkRUbEhaZU1EYS1BVEpvaVI0Yy1zeTkwUDBLOWtjcHlOQnY1TXNhRTlURzB3aXJYQUVEclNsR1hvd25CVDJhcU1lX3J2TTN4UWwzRmtJOVFj?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-13T12:00:00+00:00", "published_display": "13 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma stock hits 52-week high at 5.34 USD By Investing.com", "summary": "Arbutus Biopharma's stock reached a 52-week high of $5.34, reflecting strong investor confidence with a 56% return over the past year and a market capitalization of $1.05 billion. The company holds an \"EXCELLENT\" financial health score and its drug imdusiran recently received Fas", "url": "https://ng.investing.com/news/stock-market-news/arbutus-biopharma-stock-hits-52week-high-at-534-usd-93CH-2593526", "source_name": "Investing.com Nigeria", "published_at": "2026-07-09T17:15:49", "published_display": "09 Jul 2026 17:15", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks", "summary": "Arbutus Biopharma (ABUS) has been added to the Russell 2000 Growth Defensive and Russell 2000 Defensive Indexes, while simultaneously being removed from several value-oriented Russell indexes. This reclassification may influence the types of index-linked funds and mandates that h", "url": "https://finance.yahoo.com/markets/stocks/articles/arbutus-biopharma-abus-joins-russell-221151130.html", "source_name": "Market source", "published_at": "2026-07-09T15:11:00", "published_display": "09 Jul 2026 15:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma stock hits 52-week high at 5.34 USD", "summary": "Arbutus Biopharma's stock has reached a new 52-week high of $5.34, reflecting strong investor confidence and a 56% return over the past year. The company, with a market capitalization of $1.05 billion, has an \"EXCELLENT\" financial health score and an impressive gross profit margi", "url": "https://www.investing.com/news/company-news/arbutus-biopharma-stock-hits-52week-high-at-534-usd-93CH-4784445", "source_name": "Investing.com", "published_at": "2026-07-09T10:30:00", "published_display": "09 Jul 2026 10:30", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) Stock Looks Reasonable On Earnings But Stretched On Value", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-09T07:00:00+00:00", "published_display": "09 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABUS - Arbutus Biopharma Corp Options", "summary": "This article provides a detailed overview of Arbutus Biopharma Corp (ABUS) stock options and key financial metrics. It includes recent stock performance, company financials like market cap, income, sales, and various ratios, along with insider and institutional ownership data. Th", "url": "https://finviz.com/stock?t=ABUS&ta=1&p=d&ty=oc&ov=chain_date&e=2026-09-18", "source_name": "Finviz", "published_at": "2026-06-27T09:41:26", "published_display": "27 Jun 2026 09:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp (ABUS) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Arbutus Biopharma Corp (ABUS), noting its current valuation score of 8.58, which ranks it 115 out of 388 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of 5.38, which is slightly below ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abus/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T18:09:38", "published_display": "23 Jun 2026 18:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp (ABUS) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "The article provides a technical analysis of Arbutus Biopharma Corp (ABUS), focusing on its support and resistance levels, various technical indicators, and moving averages. It highlights that ABUS currently has a price momentum score of 8.98 and is trading between a resistance l", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abus/technical", "source_name": "TradingKey", "published_at": "2026-06-18T04:09:20", "published_display": "18 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp (ABUS) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Arbutus Biopharma Corp (ABUS) has an earnings forecast score of 8.67, ranking well within the Biotechnology & Medical Research industry. Analysts provide an average price target of $5.00 with a Buy rating. The company's expected revenue for the next quarter is $450.00K, and the E", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abus/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T23:09:10", "published_display": "17 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp (ABUS) Institutional Confidence", "summary": "The article details the institutional confidence score for Arbutus Biopharma Corp (ABUS), which currently stands at 5.00, ranking it 133rd out of 388 in its industry. Institutional shareholding has increased to 65.56%, a 3.63% quarter-over-quarter rise. The largest institutional ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abus/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T02:40:15", "published_display": "17 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp (ABUS) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Arbutus Biopharma Corp (ABUS), identifying its major shareholders, their proportional holdings, and the types of shareholders. It also provides institutional shareholding data over various quarters and lists related ETFs that hold", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-abus/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T02:39:43", "published_display": "17 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corporation (ABUS) Reports Q1 2026 Results", "summary": "Arbutus Biopharma Corporation (ABUS) announced significant Q1 2026 results, reporting $179.1 million in revenue, a substantial increase from $1.8 million a year prior, largely due to a litigation settlement with Moderna. The company swung from a $24.5 million loss to a net income", "url": "https://finance.yahoo.com/sectors/healthcare/articles/arbutus-biopharma-corporation-abus-reports-180646496.html", "source_name": "Market source", "published_at": "2026-06-13T18:06:00", "published_display": "13 Jun 2026 18:06", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (Nasdaq:ABUS) - Stock Analysis", "summary": "Arbutus Biopharma (ABUS) is a clinical-stage biopharmaceutical company focused on developing therapies for infectious diseases, particularly chronic Hepatitis B virus (HBV). The company became profitable this year, exceeding analyst expectations for its first quarter 2026 earning", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abus/arbutus-biopharma", "source_name": "Simply Wall Street", "published_at": "2026-06-12T01:09:11", "published_display": "12 Jun 2026 01:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) director awarded fully vested options on 78,800 shares", "summary": "Arbutus Biopharma director Roger Sawhney was granted fully vested stock options for 78,800 common shares at an exercise price of $4.24 per share, matching the closing price on the grant date of June 8, 2026. This equity compensation award is immediately exercisable and expires on", "url": "https://www.stocktitan.net/sec-filings/ABUS/form-4-arbutus-biopharma-corp-insider-trading-activity-ca4f1b555104.html", "source_name": "Stock Titan", "published_at": "2026-06-11T01:38:55", "published_display": "11 Jun 2026 01:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Arbutus Biopharma Corp Insider Trading Activity", "summary": "Arbutus Biopharma director Robert A. Beardsley was granted 78,800 fully vested stock options with an exercise price of $4.24 per share, expiring on June 8, 2036. This transaction is categorized as a compensation-related award, not an open-market purchase or sale. The options are ", "url": "https://www.stocktitan.net/sec-filings/ABUS/form-4-arbutus-biopharma-corp-insider-trading-activity-30701fb514c4.html", "source_name": "Stock Titan", "published_at": "2026-06-10T19:40:13", "published_display": "10 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ABUS - Arbutus Biopharma Corp Stock Price and Quote", "summary": "This page provides a comprehensive overview of Arbutus Biopharma Corp (ABUS) stock, including its latest trading data, financial metrics, analyst ratings, and recent news headlines. Key financial figures like market cap, income, sales, and employee count are listed, alongside per", "url": "https://finviz.com/stock?t=ABUS", "source_name": "Finviz", "published_at": "2026-05-29T20:09:39", "published_display": "29 May 2026 20:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Shareholders at Arbutus Biopharma (NASDAQ: ABUS) approve 2026 share plan and auditor", "summary": "Arbutus Biopharma Corporation's shareholders approved the 2026 Omnibus Share and Incentive Plan, authorizing 16,300,000 common shares for equity-based compensation. They also re-elected all director nominees, approved executive compensation on a non-binding advisory basis, and ra", "url": "https://www.stocktitan.net/sec-filings/ABUS/8-k-arbutus-biopharma-corp-reports-material-event-97792fed8f39.html", "source_name": "Stock Titan", "published_at": "2026-05-27T19:39:25", "published_display": "27 May 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Two Seas (NASDAQ: ABUS) reports 18.56M Arbutus shares; 9.4% stake", "summary": "Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi have reported a beneficial ownership of 18,557,543 common shares, representing a 9.4% stake in Arbutus Biopharma Corporation (NASDAQ: ABUS). This stake is held through two funds: Two Seas Global (Master) Fund LP and Tw", "url": "https://www.stocktitan.net/sec-filings/ABUS/schedule-13g-a-arbutus-biopharma-corp-amended-passive-investment-disc-cfc15ead65a6.html", "source_name": "Stock Titan", "published_at": "2026-05-16T00:35:59", "published_display": "16 May 2026 00:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "Arbutus Biopharma Corporation reported strong first-quarter 2026 financial results, including $179.1 million in total revenue, primarily from a litigation settlement with Moderna. The company also announced that its investigational drug, imdusiran, received Fast Track designation", "url": "https://finance.yahoo.com/news/arbutus-reports-first-quarter-2026-113000313.html", "source_name": "Market source", "published_at": "2026-05-14T00:40:17", "published_display": "14 May 2026 00:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp reports results for the quarter ended March 31 - Earnings Summary", "summary": "Arbutus Biopharma Corp (ABUS) has reported its financial results for the quarter ended March 31. This earnings summary provides a brief overview of the company's performance during the specified period.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41Q1M1:0-arbutus-biopharma-corp-reports-results-for-the-quarter-ended-march-31-earnings-summary/", "source_name": "TradingView", "published_at": "2026-05-14T00:09:11", "published_display": "14 May 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Swings to Profit in Q1, Revenue Rises; Shares Up Pre-Bell", "summary": "", "url": "https://finance.yahoo.com/news/arbutus-biopharma-swings-profit-q1-114714905.html", "source_name": "MT Newswires", "published_at": "2026-05-13T11:47:14+00:00", "published_display": "13 May 2026 11:47", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma earnings beat by $0.91, revenue topped estimates", "summary": "Arbutus Biopharma (NASDAQ: ABUS) exceeded analyst expectations for its first-quarter earnings, reporting an EPS of $0.870 against an estimated $-0.040. The company's revenue also significantly topped estimates, coming in at $179.23M compared to the consensus of $400K. The stock h", "url": "https://www.investing.com/news/earnings/arbutus-biopharma-earnings-beat-by-091-revenue-topped-estimates-4684337", "source_name": "Investing.com", "published_at": "2026-05-13T12:39:54", "published_display": "13 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 90, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) Reports Strong Q1 Earnings with $0.87 EPS", "summary": "Arbutus Biopharma (ABUS) reported strong Q1 earnings with a GAAP EPS of $0.87 and revenue of $179.1 million, significantly boosted by a litigation settlement with Moderna. The FDA also granted fast track status to its lead asset, enhancing growth prospects. Despite a strong finan", "url": "https://www.gurufocus.com/news/8855072/arbutus-biopharma-abus-reports-strong-q1-earnings-with-087-eps", "source_name": "GuruFocus", "published_at": "2026-05-13T12:39:54", "published_display": "13 May 2026 12:39", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/arbutus-q1-earnings-snapshot-113607386.html", "source_name": "Associated Press", "published_at": "2026-05-13T11:36:07+00:00", "published_display": "13 May 2026 11:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp 1Q 2026: Revenue $179.13M, EPS $0.87\u2014 10-Q Summary", "summary": "Arbutus Biopharma Corp reported a significant increase in first-quarter 2026 revenue to $179.13 million and diluted EPS of $0.87, driven primarily by a $178.7 million licensing settlement with Moderna. The company also highlighted pipeline progress for imdusiran, which received F", "url": "https://www.tradingview.com/news/tradingview:eefe9e5400205:0-arbutus-biopharma-corp-1q-2026-revenue-179-13m-eps-0-87-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-13T11:39:54", "published_display": "13 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna settlement drives Arbutus (NASDAQ: ABUS) to $169.7M Q1 profit", "summary": "Arbutus Biopharma reported a significant Q1 2026 profit of $169.7 million, primarily driven by a $178.7 million license revenue from its share of Genevant's settlement with Moderna. This settlement, which includes a noncontingent payment and a potential contingent payment of up t", "url": "https://www.stocktitan.net/sec-filings/ABUS/10-q-arbutus-biopharma-corp-quarterly-earnings-report-e2a90b2069e8.html", "source_name": "Stock Titan", "published_at": "2026-05-13T11:39:54", "published_display": "13 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus (NASDAQ: ABUS) swings to Q1 profit on $179M revenue surge", "summary": "Arbutus Biopharma (NASDAQ: ABUS) reported a significant turnaround in Q1 2026, swinging to a net income of $169.7 million on $179.1 million in revenue, primarily driven by a litigation settlement with Moderna. The company expects to receive $178.7 million from a $950 million upfr", "url": "https://www.stocktitan.net/sec-filings/ABUS/8-k-arbutus-biopharma-corp-reports-material-event-9c010d7c3df7.html", "source_name": "Stock Titan", "published_at": "2026-05-13T11:39:53", "published_display": "13 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 91, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma: A Fascinating HBV Story, But Still Too Early (NASDAQ:ABUS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNRlZjVnZsODlzQTVtQTREOC1mdjNvSkdWTW5QNnNWeHdSZ1l2OUk2aS1Oa3VNNzE3YjM4alhra1kteGlVaThIWGNNLUtmLVI0YWZ0Z2RpNGtacFNnUTAxRjc1UG1qVVpDMXRSNnc3R1h4WnRDQzI4SnpDQnc0N2pyVEZLWGtQRG1oUWhCUjExR3RyTnFkY203eVBrRERIM3VHbzlNZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxObl9XWW5Ic2JBNUpoSWltc1pHb0o5aWJRZk1NRzZ2VGpyUTRCMjduVTN4N3ZjdVYwY2RGS3dBOWo3TlFTNWQtRnF6YkRNMG44eVdRMU5TOFA5YmtTNHFHSWpYMXZ0ZTZOaW1TRGRtUHJoRXlrbThnSTF4UEhnZ3h5MlNyZ2R6UzJkOXlZUm9fSGFyaDk4ODlqaDlxRnNrWHdj?oc=5", "source_name": "Market source", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxQSXJKN05RQ2l5V2dudzlLYWt0dUIwSG84R1k2SHEtaUhxVElQeldnWDRINE1FMFlEa0FMczFFbzh5TjN5cEc3WEZ1dWhTMzFoMnZqeUlGZ1FHSnBCWlFueUZuNDI0aDhIbjhCSWIwc05aTnJNV3d2RU9CTnJoTVplek9HTl9PcUU5RmxuX0kwek5Ba2JkM09SS0pQT2RYeFZnSEE?oc=5", "source_name": "Market source", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxNdTRuMEY3c0p2dWVlMkRPc1FVcHFwelZ1czA3b2VVTVF5SGJJOGRoMVBoRTFDOWJfbU1hXzBSU1RKRVFhdmREaDRleXFrbXh5bmoyMmZTV25BM0JPQ3A4N2xpMjhra211Y1lWbXpHM1dDVWdqUEpiTl91d2hfaVluWGVVc1UxWEdpVGlEdS1EZHdIOHg0M3ZKa0V5dGlyYjhGLUpXV0FGSmJSdw?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corp ($ABUS) Former Interim President and CEO 2025 Pay Revealed | ABUS Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNTUNWYzRqSm5LR1VadjdUV0Z0RTA1cE81WHBWbXNNSUxtdjVNVGFaYUZfWDZ2cGlEMmt3QWZCX0Jlc0tHOUJzZGdMck9uNmhRSE1EaTR5YTZFZk5fNW96X3A4Njltb0FxWFc1TzM2OUhnZ3YwS1JjR1kwYllUaFBDVkl0a3NzclVyMVVCbFZJeFJjSEtCQV9GYm13QUJ0bThIc3Z0VXJnZW9rd080SzRvbVplb0xXMlQtUEpvbw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma (ABUS) Q3 Loss And Revenue Drop Challenge Bullish Profitability Narratives", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxQOTk3RUxMSmcxWmkxWElweWx4T08xQ1RBTnBuQld2Vm4wZXc5ZnJWcjFVV1NESTRkejFNeV9WS1N2VnBiOUdDazl5elFZOXRjMUZRa191NVZQb09aZk1kSF9aLWJ3eUhGaEdLRVNYVUI3WWJzeGt1OGZURzdlZ3ZoOElaUGV4dkQ5S0tEd1k5ckFKbENLUUd4dGcwNi1NTGZBNVRhN1Nya2VIM1dwYXJmakh6VDM4bzAyZ3l0UzBadEQ3aWd3aWJSWTJXV3prWU4td1pPTVpKc2JlVnRUck9QZnpyX2RtUdIB6wFBVV95cUxQM0l5YjhNU1huZ1hXZ1lCam1QbmNQMVdJcDR0aGk2ZlpUQXdzNmFvOE5LZUdtX196TWtqbGZqOTMwRndVM0xvSjdGTmlMVXJoaS1VZjN6SjdmaHVUNlplMXRvU1loTnVTU1V3NkRMU2xtTkxVSW52dS1DWVBlZVpYeldYbG1qTWxTYjVubENWZVlYTlFZTTljazFMTFVDZTRhY2M2OTJXYTVBOGVSMDg5RVdTY3AtY29oOVcxUXg2U2JBOUJ1QmxYVU1XOW1TeWpFUTE0QS16azZvam5TZDViVmZrbWhLQ05keVVr?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNbnk4YVVtS0dKamplaGRucDhPcm9wLUpOMTYwMWdXNFAyZlBKS09rM3JIcmFLMURiTWgwYWFDeDlnLUJQZ1JFQjd3czF5ZE80TG9FMzhZUWQ0Z055Z1JseENuSEFyYmhQNmw5MnhqeTFyQm1KWFczdTM1TDZWc0dUWWt2NTFJbUlOa3laSTlidGw0OXpReS1TT1U2UlQ2ZEZRX01tZlJB?oc=5", "source_name": "Market source", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Moderna-Arbutus-Genevant Patent Settlement: Wall Street Says Not Best-Case Scenario But Removes Overhang For MRNA Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwJBVV95cUxOckYwNGExSUtWSE1aZmFCRDdyX0dZZUk2a242WndQZFBpWk8wcnF0bjY5Vnp2ZzNzLWNVRFlGdjBKTFctY2hVeWZhOHpFRHNSb3hJYmp2T1FISHlwVld5RUIwaEVUSnNlNE9salg3SFBnc0VEUzUtNm1XZFhnVU1KSnRtcUpMaTlxUmxabWptTVAtOWFTZVZvaHhLUXJ0eFhlUDYxaWREUXBiQllReTJhZ1dtZGdDXzI1UTR0QnlXbFNxckljUmkxZkpmWEtfMXZUUWZpUjBOUzNqTjNIcUdBampDWVBWWFNDTUFqN0I2NGx2VURiSk9McXFiWTdVWnN5bGRRODJMTXVGNGZVT1E4?oc=5", "source_name": "Stocktwits", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna", "summary": "", "url": "https://news.google.com/rss/articles/CBMi_AFBVV95cUxPX005QmFWeDhvalp1c0Nla1k0MC1oZlNHLUlEdFp5REZYaFVFaUp3Vmo5ak44a29PSjZsaHRFTV9ObFFPY0l3NFpHMFJ6T1A3eHY1Q1U4d0s2QXVGU0NTOS0tZEhKcUw2Z2tUbXZiWkhBRHhvVGhTRlF4dmt5clh4ajJNRC1DNHU2MV8tdGtIU2ZVTzlCV2pEWFhCQkxLSVhhMUhNRjhtOVFpbG9jSW9GcWQxb09KSVZCdW5uSF84RmtsaEhibmltN1RfcjlrRDk0bVJPeW9Da3ZvUHhhREVSVlJOdk9qTU8xeUp2SWhZaG8xX0lHYWhsbWo0RFE?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "European Patent Office revokes Arbutus Biopharma patent following appeal", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxNN0cxRWkyNkU4RFJteU95eVdYeS1haG4wdE9wRkZ5STcweEg0emVNbW9KUnNuZzREV0w1MkFCRGZHd1ZEQlZ3bUhoZHJiOHZxMmZOYm1MZWZVdEpBR3R5dHdxRldEejhDNHRfQVBfNzhFUXEtbTY2NllsVXFDU0hGM3JpNExiOERNUko3VE0yUmRMUVNCQmpna0JqeHVBVkxVclppOGR6bWRQQzRpUDdxT3RuVVRaUk1nTWZueHNUUTdnUFo2TjA4?oc=5", "source_name": "Investing.com", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus falls as patent dispute with Moderna hits EU snag", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiwFBVV95cUxPTkM2RTNaMFlfUHlTNGU2VzNSVnVfTlFfS1ZnQjJ1bGF5aXhsOGNYVlROLU1RVXZ1bElRTmVHNUlhSGVmTEIwY0FiZlVpRnd2c3Vtdmc5dERCUmVaX0VWMW9YeWQ5OE1WN0ZfSUQ3SWtueUpkWlhxSHlfTW9kNUU0LUxybk1Dc1pyb1Zn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharma Corporation (ABUS) Stock Price Today: $4.74", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE93NnRvQV91Ri05VWkzdXpsdTlNTmZwUTFFem8tVkFnRmd6MjdtWmtDZmZjMUlYRnpZSmFmeGM2QnM4OWVDWmVvOVBFelNLTFFITVNPQU1Nbw?oc=5", "source_name": "Gotrade", "published_at": "2026-01-13T00:30:45+00:00", "published_display": "13 Jan 2026 00:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Arbutus Biopharm (ABUS) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE5pTjAzRUd4S2N3eXk0SUR4ajFCVXhMLUxscUp5ajZiSEJKRG5RMmFWUjdjREczekU3SGxMRVBESmZKcnJnNGxZRWNEam03UzBpcHFn?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:02:24+00:00", "published_display": "25 Apr 2025 00:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 100, "total_relevant": 58, "sentiment_summary": {"positive": 21, "negative": 3, "neutral": 34, "score": 58, "total": 58, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 14.25, "count": 24}, {"event": "earnings", "label": "Earnings", "weight": 12.86, "count": 25}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "capital_return", "label": "Capital return", "weight": 1.1, "count": 2}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 4.56, "latest_week": "2026-07-17", "one_week_move": -5.0, "four_week_move": 0.2, "twelve_week_move": 8.6, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.111495, "market_dynamics_buy_signal": false, "relative_strength": -4.341466, "fair_value_gap": 32.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 50.3753, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.0% over one week, +0.2% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 13}, {"label": "Stock Titan", "count": 9}, {"label": "GuruFocus", "count": 5}, {"label": "TradingKey", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "Seeking Alpha", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "TradingView", "count": 3}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 25}, {"label": "Market update", "count": 24}, {"label": "Regulatory and legal", "count": 4}, {"label": "Capital return", "count": 2}, {"label": "Balance sheet", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-5.0% over one week, +0.2% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Arbutus, Sanofi escalate mRNA patent fights; InnoCare\u2019s TYK2 contender advances"}], "updated_at": "2026-07-22T09:11:10.046268+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}